Boca Biolistics
Founded 2005 · 28 employees on LinkedIn · 3 known investors
Boca Bio provides biospecimen sourcing for life sciences research through its BioSpecimen360 offering. It serves researchers who need access to biological specimens.
Also known as Boca Bio · Boca Biolistics Reference Laboratory · Boca Biolistics, LLC · BocaBio
Investors · 3
Also in the syndicate · 2
Company profile
researched Aug 2026Boca Biolistics, LLC is a Pompano Beach, Florida-based life-sciences services company that combines a biospecimen bank, contract research organization (CRO) services and a reference testing laboratory. Its offerings include human biospecimen supply from inventory, custom and prospective biospecimen procurement, sample characterization, central laboratory testing, biostorage, data management and end-to-end clinical research services, delivered from early discovery through product development and launch.
The company operates a CAP-accredited, CLIA-certified central laboratory that performs molecular and immunoassay testing, method comparison studies and validation studies used by clients in regulatory submissions. Project management, data operations and biobanking functions are organized under directors for clinical research operations, laboratory services, biospecimen solutions, data operations and the biobank group. Company materials describe a global sourcing network spanning five continents, with figures cited on its site of 50–60 countries and 100–200+ collection sites, while a 2023/2024 announcement describes a biospecimen bank with samples from over 40 countries and a clinical site network across 14 countries, both on five continents.
Leadership includes CEO Valentin Adia, COO Michael Morris, CFO Joseph Burick, Medical Director Dr. Harold Alvarez and VP of Sales Richard Saldaña, with board members including Sebastien Dhonte (Clairvest), John Mills and Ian MacDonald, and a scientific advisory board. Frederick L. Kiechle, MD, PhD, is identified as Chief Medical Officer of Boca Biolistics Reference Laboratory in published posters.
Founding story
The company was started as a biobank focused on quickly supplying ethically collected, high-quality, annotated biospecimens to researchers, growing from roots in science and analytics into broader clinical research and laboratory services as sponsor needs expanded.
Business model
Fee-for-service provider to life-sciences organizations: sale and custom procurement of human biospecimens, central laboratory testing, biostorage and data management, and clinical research services, which can be bundled into a single project scope customized to a study's specimen, testing, data, site and regulatory requirements.
Revenue is generated from biospecimen sales and custom collections, laboratory testing services (including method comparison and validation studies), biostorage and data management, and clinical research service contracts; a third-party profile estimates annual revenue in the $1M–$10M range.
Traction
Reports more than 20 years as a biospecimen and clinical research services provider, a collection network spanning five continents and 100+ (site also cites 200+) collection sites, client testimonials from diagnostics developers in the US and Taiwan, published posters and peer-reviewed collaborations (including SARS-CoV-2 detection studies and dengue subtyping work), and a strategic partnership with Oxford BioDynamics announced in November 2020.
Latest developments
Clairvest Group and Clairvest Equity Partners VI made a US$25 million equity investment in February 2023, with Clairvest working alongside CEO Valentin Adia and COO Michael Morris to accelerate growth, expand oncology capabilities and increase presence in the pharmaceutical industry. The company has also introduced Boca BioSpecimen360, a biospecimen sourcing offering promoted across its website.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Positions itself as an integrated, end-to-end clinical research partner combining biobank, CRO and reference laboratory capabilities under multiple certifications, with more than 20 years operating in biospecimen supply; third-party profiling places it in the biotechnology research sector with mid-market scale (11–50 employees, roughly 30 reported).
Integration of biospecimen sourcing, prospective collection, central laboratory testing, biostorage, data management and clinical research services within a single vendor, supported by a global collection network, regulatory documentation for purchased biospecimens, and CAP/CLIA, ISO and ACRP certifications.
Technology
CAP-accredited, CLIA-certified central laboratory performing complex molecular and immunoassay testing, method comparison and validation studies; ISO-certified biospecimen inventory and ACRP/CCRA-certified clinical research services; biobanking and biostorage infrastructure with annotated sample data and data-management capabilities, marketed in part through the Boca BioSpecimen360 sourcing offering.
Go-to-market
Direct sales organization (VPs of sales and regional sales team) serving diagnostics, IVD, biotech and pharmaceutical clients, supported by an online biospecimen inventory and BioSpecimen360 sourcing platform, published posters, case studies and blog content, plus partnerships with industry players such as Oxford BioDynamics.
Diagnostics and in vitro diagnostics (IVD) companies, biotechnology and pharmaceutical firms, clinical research organizations, principal investigators and clinical laboratories developing assays, diagnostic platforms, therapeutics, vaccines, biomarkers and companion diagnostics.
Geography
Headquartered in Pompano Beach, Florida, United States, with a biospecimen sourcing and clinical site network spanning five continents; company site cites 50–60 countries and 100–200+ collection sites, while the 2023 investment announcement cites samples from over 40 countries and clinical sites in 14 countries. A third-party profile lists employees across North America and South America.
History
Founded in 2005 and, per company statements, active since 2007 as a partner in diagnostic device and therapeutic R&D, the business began as a biobank supplying ethically collected, annotated samples with rapid turnaround. It subsequently added prospective and custom procurement of hard-to-source specimens through a Clinical Research Services division, then built an in-house CAP-accredited, CLIA-certified central laboratory for method comparison and validation testing, positioning itself as an end-to-end clinical research partner. In 2023 Clairvest Group made a US$25 million equity investment alongside the founders and management team.
Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsClairvest Group Inc. (TSX: CVG), together with Clairvest Equity Partners VI, made a US$25 million equity investment to acquire an equity stake in Boca Biolistics, partnering with CEO Valentin Adia and COO Michael Morris for the next phase of growth. It was Clairvest's second life-sciences investment.
$25M source ↗
Oxford BioDynamics announced a strategic partnership with Boca Biolistics, described as a US-based biorepository, reference lab and contract research organization.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 7
primary sources listed
- Boca Biolisticsbocabio.com · web
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Boca Biolistics do?
- Florida-based biobank, CRO and CAP/CLIA reference laboratory supplying biospecimens and clinical research services worldwide.
- Who are Boca Biolistics's investors?
- Boca Biolistics's investors include Clairvest Group Inc.